Selecta Biosciences Announces Upcoming Clinical Presentations WATERTOWN, Mass., June 06, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...

ProteoThera, Inc. Receives Allowance for a Broad U.S. Patent Covering Matrix-Binding Technology Platform Newton, MA, May 09, 2016 (GLOBE NEWSWIRE) -- ProteoThera, Inc., a biotechnology company with a platform technology for local, targeted drug delivery, announced today that a notice of allowance has...

CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate NEWARK, Calif., Jan. 20, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high...

Gout & Uric Acid Education Society Calls New Guidelines on Gout Management an Important Milestone, Publishes Response for Physicians and Patients PITTSBURGH, Oct. 31, 2012 (GLOBE NEWSWIRE) -- As the American College of Rheumatology prepares for its annual meeting in November, the Gout & Uric Acid Education Society has responded to recently...